NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus” or the "Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer ...

Sickle cell disease (SCD) altered CD8+ T-cell chromatin architecture, triggering ferroptosis and weakening antitumor immunity ...

A pair of recent studies from the laboratory of Bin Zhang, MD, Ph.D., the Johanna Dobe Professor of Cancer Immunology, have ...

These cDCs present brain-derived antigens to T cells sitting in the cervical lymph nodes. In ApoE4 carriers, CD8+ T cells more easily cross from the blood into the brain. In tauopathy mice, antigens ...

As people age, their immune systems become less efficient, posing a challenge for cancer therapies that rely on harnessing ...

The mouse-based study, published in the Journal of Experimental Medicine, uncovered a new way to enhance stem cell-like memory CD8+ T cells following vaccination, pointing to a future where more ...

The mouse-based study, published in the Journal of Experimental Medicine, uncovered a new way to enhance stem cell-like memory CD8+ T cells following vaccination, pointing to a future where more ...

A phase I study of a next-generation CAR T cell therapy showed a 52 percent complete remission rate for patients with relapsed/refractory lymphoma. A next-generation "armored" CAR T cell therapy ...

A next-generation "armored" CAR T cell therapy showed promising results in a small study of patients whose B-cell lymphomas continued to resist multiple rounds of other cancer treatments ...

A next-generation, anti-CD19 enhanced CAR T-cell therapy that secretes interleukin-18 achieved a response in 81% of lymphoma patients who failed previous CAR T-cell therapy. Duration of response ...